On April 16, 2021, ZebiAI Therapeutics, Inc., an artificial intelligence company that pioneers the application of machine learning to massive datasets to enable drug discovery, and Relay Therapeutics, Inc. (Nasdaq: RLAY) announced that they have entered into a definitive merger agreement pursuant to which Relay would acquire ZebiAI for $85 million of upfront payments, composed of $20 million in cash and $65 million in Relay common stock, plus up to an additional $185 million of contingent payments based on the achievement of certain platform- or program-related milestones, payable in Relay common stock, and a percentage of the proceeds of certain agreements entered into by Relay, payable in cash. 

WilmerHale is representing ZebiAI in the deal, with a team led by Chris Barnstable-Brown, Ariel Soiffer and Jenna Ventorino, which also included Samantha Berkovits, Erin Anderson and Elijah Soko on corporate and M&A matters, and Scott Kilgore, Julie Hogan Rodgers and Meghan Walsh on employment, equity compensation and tax matters.